- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03848663
Visual Remapping to Aid Reading With Field Loss
Remapping the Visual Field to Aid Reading With Central Scotomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Following initial characterization of their visual field loss, the participant's performance in reading tasks will be measured with and without remapping. Tasks will include reading groups of random letters, words, simple sentences, and "natural" text from the environment (taken from phone apps, signage, etc). Different kinds of remappings will be used by participants, including traditional and personalized remapping. For control observers, differently shaped artificial scotomas will be used.
Participants interested in the study will be brought in for an initial visit. All participants will be administered the MMSE. Observers who pass the criteria for the study will then have the remainder of the procedures described to them verbally prior to undergoing the remainder of the consent process (see below). Participants will then undergo a standard exam at the UMN eye clinic, if they have not had one within the last month.
Participants will then have their scotomas mapped using a microperimeter housed in the psychology department to give size and shape information. Additional perimetry may also be conducted using either of the two displays (either HMD or desk mounted computer monitor) we have developed. Here, patients will be asked to fixate at a spot on screen and identify visual stimuli presented at different regions of the screen. The size and locations of visual stimuli patients were unable to identify will provide the size and location of the scotoma. Another additional manual perimetry protocol may be conducted as well. This would involve asking subjects to fixate at the center of a tangent screen, and asking them to identify dots temporarily presented on the screen by the researcher using a laser pointer. The locations of dots that patients are unable to identify will provide the size and location of the scotoma. The location and extent of each eye's scotoma and PRL will be used as software inputs on either device. Perimetry using one or all of the methods above will be performed until acceptable information about the scotoma extent and location is obtained.
In a second visit, participants will perform the visual tasks that are used as the basis of their personalized remapping, letter perimetry. Participants will first view and report three randomly selected horizontally arranged letters placed at different locations in the visual field. This letter perimetry task will take about 40 min and will cover a large part of the visual field.
Participants will then read single words whose letters have been displaced from horizontal in various ways that comprise candidate remappings generated on the basis of the letter perimetry results. This personalization test will take about 40 minutes, and will find a good remapping strategy for the individual. Subjects will then be introduced to the reading tasks that comprise the remainder of the study
In 6 additional sessions, participants will perform various reading tasks using different remappings. In all of these, text will be displayed on the screen, and the task is simply to read aloud what was presented. Two sessions will involve reading single words, one session will involve reading strings of 3 letters that are not arranged horizontally, two sessions will involve reading short sentences, and one session will involve reading naturalistic text (from phone apps, signage, menus, etc). In all sessions, some reading will be with remapping, some will be without. Both traditional and personalized remapping will be used.
In all these sessions, the eye tracker will be calibrated to participants' individual head and eye position. This will involve fixating at different points on the device screen (HMD or desk-mounted) as the eye is imaged by the eye trackers. This may take up to 45 minutes in the initial session, if various combinations of head and eye positions are required for the eye trackers to work well. But once completed, calibration is much faster in subsequent sessions. Quick perimetry validation may also be conducted in each session.
Throughout all testing, patients will be asked if they feel any discomfort, and will be able to take a break or quit testing at any point.
Including the initial visit, testing for any given patient is anticipated to last no more than eight sessions over eight weeks. Enrolling participants, testing, and data analysis for all participants is anticipated to take five years from the date of enrollment of the first participant.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stephen Engel, Ph.D.
- Phone Number: 612-625-5571
- Email: engel@umn.edu
Study Contact Backup
- Name: Gordon Legge, Ph.D.
- Email: legge@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Stephen Engel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 16 years or older
- Central vision loss of at least 5 deg diameter, including the fovea, from bilateral central scotomas
- Stable fixation (+/- 1 deg) using their PRL.
- No cognitive impairment as indicated by a Mini-Mental State Examination (MMSE).
- Satisfactory calibration achievable using eye tracker
Exclusion Criteria:
- Central vision loss of less than 5 deg diameter; scotomas that do not cover the fovea; unilateral scotomas
- Poor fixation (worse than+/- 1 deg) using their PRL.
- Cognitive impairment as indicated by a Mini-Mental State Examination (MMSE).
- Satisfactory calibration not achievable using eye tracker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with scotoma
No remapping (control condition), traditional remapping, personalized remapping
|
Shifting text outside of scotoma
Shifting text based on individual letter-based perimetry
|
Active Comparator: Normally sighted with artificial scotoma
No remapping (control condition), traditional remapping, personalized remapping
|
Shifting text outside of scotoma
Shifting text based on individual letter-based perimetry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reading Speed for Individual Words
Time Frame: Measured during third visit- each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
How quickly participants can correctly read displayed text
|
Measured during third visit- each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Reading Speed for Sentences
Time Frame: Measured during fourth visit- each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
How quickly participants can correctly read displayed text
|
Measured during fourth visit- each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Reading Speed for Natural Text Samples
Time Frame: Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
How quickly participants can correctly read displayed text
|
Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Reading error rate for Individual Words
Time Frame: Measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
How many mistakes participants make
|
Measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Reading error rate for Sentences
Time Frame: Measured during fourth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
How many mistakes participants make
|
Measured during fourth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Reading error rate for Natural Text Samples
Time Frame: Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
How many mistakes participants make
|
Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eye fixation quality for words
Time Frame: Measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Variance of x and y eye position coordinates computed during fixation periods while reading
|
Measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Eye fixation quality for sentences
Time Frame: Measured during fourth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Variance of x and y eye position coordinates computed during fixation periods while reading
|
Measured during fourth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Eye movement quality for sentences
Time Frame: Measured during fourth visit
|
Number off leftward (regressive) eye movements during sentence reading
|
Measured during fourth visit
|
Eye fixation quality for natural text samples
Time Frame: Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Variance of x and y eye position coordinates computed during fixation periods while reading
|
Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Eye movement quality for natural text samples
Time Frame: Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Number off leftward (regressive) eye movements during natural text reading
|
Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen Engel, Ph.D., University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REMAP002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
Clinical Trials on Traditional Remapping
-
IRCCS San RaffaeleCompleted
-
Qianfoshan HospitalNot yet recruitingHepatic Encephalopathy | Cirrhosis, Liver | Portosystemic ShuntChina
-
Shengjing HospitalRecruitingPlasma Cell MastitisChina
-
Hasan Kalyoncu UniversityCompletedMultiple Sclerosis | Muscle Spasticity | Cervical Region Disorder Nos | Pressure AreaTurkey
-
Hebrew SeniorLifeCompleted
-
University of RochesterCompletedEducation, Medical
-
Henan University of Traditional Chinese MedicineUnknownCommunity-acquired PneumoniaChina
-
October 6 UniversityCompleted
-
University of MichiganMassachusetts General Hospital; National Center for Complementary and Integrative...Completed